Amarin Corp plc (NASDAQ: AMRN) reported Q3 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13).

Recognized $14.1 million in product revenue from Vascepa® (icosapent ethyl) sales in Q3 2014 compared to $12.6 million in Q2 2014 and $8.4 million in Q3 2013, an increase of 12% and 68%, respectively

For earnings history and earnings-related data on Amarin Corp plc (AMRN) click here.